Search | Clinical Trials Finder

Conditions: COVID-19
Interventions: Interferon beta-1a, Placebo, Remdesivir; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 969 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 55
States / cities: Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: CodaVax-RSV, Normal Saline; Biological
Lead sponsor: Codagenix, Inc; Industry
Eligibility: 6 Months to 5 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Lincoln, Nebraska • Omaha, Nebraska • Providence, Rhode Island + 1 more

Conditions: Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Interventions: Ketamine, Normal Saline; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Abortion, Dilation and Evacuation, Hemorrhage, Prophylactic Tranexamic Acid Use, Blood Loss
Interventions: Tranexamic Acid, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 276 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: San Diego, California • Chicago, Illinois

Conditions: Cytomegalovirus
Interventions: mRNA-1647, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 9 Years to 25 Years
Enrollment: 873 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 44
States / cities: La Mesa, California • Sacramento, California • Fort Collins, Colorado + 38 more

Conditions: Acute Ischemic Stroke, Cerebral Stroke
Interventions: Drug: Normal Saline, Sovateltide; Drug
Lead sponsor: Pharmazz, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 14
States / cities: Tucson, Arizona • Carmichael, California • Oxnard, California + 10 more

Conditions: Breast Cancer, Non-Hodgkin's Lymphoma
Interventions: Mesna, Saline, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: Mara Chambers; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Achondroplasia
Interventions: BMN 111, Normal Saline; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 22 Years to 45 Years · Male only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Acute Respiratory Distress Syndrome, ARDS
Interventions: ExoFlo, Intravenous normal saline; Biological · Other
Lead sponsor: Direct Biologics, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 32
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Davis, California + 29 more

Conditions: Healthy
Interventions: ketorolac, placebo, remifentanil, Capsaicin; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Non-small Cell Lung Cancer, NSCLC
Interventions: Tislelizumab, Ociperlimab, Pembrolizumab, Placebo; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 669 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 9
States / cities: Fullerton, California • Los Angeles, California • Ocala, Florida + 6 more

Conditions: Atrial Fibrillation
Interventions: (R)-propafenone, (S)-Propafenone, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: COVID-19, Acute Respiratory Distress Syndrome, Acute Respiratory Failure
Interventions: Sodium Nitrite, Normal Saline; Drug
Lead sponsor: Hope Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Tampa, Florida • Fort Worth, Texas

Conditions: Spinal Deformity, Degenerative Lumbar Spinal Stenosis, Blood Loss, Surgical
Interventions: Tranexamic Acid 100 MG/ML, Placebo; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Lassa Fever
Interventions: LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, Normal Saline Placebo, LASSARAB+ aPHAD-SEat 1400rU; Biological · Other
Lead sponsor: Wilbur Chen, MD, MS; Other
Eligibility: 18 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Iron Deficiency Anemia, Pregnancy
Interventions: Ferric derisomaltose, Ferrous sulfate; Drug
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Miami, Florida • Ann Arbor, Michigan + 4 more

Conditions: Post Operative Pain
Interventions: 0.25% bupivicaine will be injected at the study port site prior to incision, Saline will be injected at the study port site prior to incision, Saline will be in injected into the port site prior to closure, 0.25% bupivicaine will be injected into the port site prior to closure; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Down Syndrome
Interventions: Insulin glulisine, Saline; Drug
Lead sponsor: HealthPartners Institute; Other
Eligibility: 35 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Influenza
Interventions: NasoVAX; Biological
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Post-operative Surgical Pain
Interventions: Nerve Block with ropivicaine 0.5% Injectable Solution, Nerve Block with Placebo sham control of 0.9% Normal Saline; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Nausea, Postoperative
Interventions: QUEASEEase aromatherapy quick tab, Placebo product; Other
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years to 99 Years
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Chronic Hepatitis B
Interventions: ARC-520, Placebo, Entecavir, Tenofovir, diphenhydramine; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: San Francisco, California • Miami, Florida • New York, New York + 1 more

Conditions: Thyroid Eye Disease, Graves' Orbitopathy
Interventions: Teprotumumab, Placebo; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 9
States / cities: Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 6 more

Conditions: Non-small Cell Lung Cancer
Interventions: pembrolizumab, pemetrexed, carboplatin, cisplatin, saline solution; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 19
States / cities: Los Angeles, California • Monterey, California • Orange, California + 14 more

Search by objective public record fields.

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children

Intravenous Ketamine for Treatment-Resistant Depression

Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers

Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

Effect of Spinal Ketorolac After Acute Opioid Exposure

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

New Formulations of Propafenone to Treat Atrial Fibrillation

Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite

Tranexamic Acid in Adult Spinal Deformity Surgery

DMID 23-0015; Lassa Fever CVD 1000

Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy

Study to Compare Reduction in Pain After Surgery With and Without Local Anesthesia During Laparoscopy

Investigation of the Safety of Intranasal Glulisine in Down Syndrome

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Regional Anesthesia (Supra-Orbital and Infra-Orbital Nerve Block) (SION) for Pain Management in Trans-sphenoidal Hypophysectomy

Effects of Aromatherapy on Nausea Levels

Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)